Publication: Estudio longitudinal del rendimiento neuropsicológico, neuropsiquiátrico y motor en la enfermedad de Parkinson
Loading...
Official URL
Full text at PDC
Publication Date
2016-08-23
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
La enfermedad de Parkinson (EP) es una enfermedad progresiva, crónica e incapacitante cuyos síntomas principales son el temblor de reposo, la rigidez y la bradicinesia, apareciendo en el transcurso del tiempo la inestabilidad postural. Las alteraciones cognitivas y del estado de ánimo son otra de las características de esta enfermedad, pudiendo constituir una de sus complicaciones más incapacitantes. Ni el deterioro cognitivo leve (DCL) ni la demencia (D-EP) son fáciles de definir ni de evaluar. Algunos autores describen el DCL como una fase premórbida de la demencia (Pigott et al, 2015) aunque no todos los pacientes evolucionan a D-EP. La prevalencia de la D-EP es de 20-40% (Aarsland, Anderson et al, 2001), siendo algunos de los factores de riesgo la edad avanzada al diagnóstico, los síntomas motores más graves, sobre todo los relacionados con el trastorno de la marcha y la inestabilidad postural, el deterioro cognitivo leve, la depresión, el déficit temprano en fluidez verbal, la aparición de alucinaciones o la escasa respuesta al tratamiento con levodopa (Emre, 2003). El perfil de demencia en la EP es de tipo frontosubcortical, con déficits en las funciones atencionales y ejecutivas, mnésicas, visoespaciales, la fluidez verbal y las praxias...
Parkinson disease (PD) is a progressive, chronic and disabling condition whose main symptoms are resting tremor, rigidity and bradykinesia with postural instability appearing in the course of time. Cognitive and mood disorders are other features of this disease and these may constitute some of the most disabling complications. Mild cognitive impairment (MCI) or dementia (D-PD) are difficult to define and evaluate. Some authors describe the MCI as the premorbid phase of dementia, although not all patients progress to D-PD. The prevalence is 20-40% (Aarsland, Anderson et al, 2001) and some of the risk factors are older at diagnosis, more severe motor symptoms such as gait and postural disability, mild cognitive impairment, depression, early deficits in verbal fluency, hallucinations or poor response to levodopa (Emre, 2003). The profile of dementia in PD is frontosubcortical type with deficits in attentional, executive, mnesic and visospatial functions, verbal fluency and praxis. The investigation began in 1999, by posing the evaluation of a cohort of patients with PD using neuropsychological tests and their correlation with the image of single photon emission computed tomography (SPECT), by the intravenous injection of a radioactive drug (99mTc HMPAO) to evaluate cerebral blood flow in different areas of the cerebral cortex and basal ganglia. The follow up was thought to be performed at 5 years of the first evaluation...
Parkinson disease (PD) is a progressive, chronic and disabling condition whose main symptoms are resting tremor, rigidity and bradykinesia with postural instability appearing in the course of time. Cognitive and mood disorders are other features of this disease and these may constitute some of the most disabling complications. Mild cognitive impairment (MCI) or dementia (D-PD) are difficult to define and evaluate. Some authors describe the MCI as the premorbid phase of dementia, although not all patients progress to D-PD. The prevalence is 20-40% (Aarsland, Anderson et al, 2001) and some of the risk factors are older at diagnosis, more severe motor symptoms such as gait and postural disability, mild cognitive impairment, depression, early deficits in verbal fluency, hallucinations or poor response to levodopa (Emre, 2003). The profile of dementia in PD is frontosubcortical type with deficits in attentional, executive, mnesic and visospatial functions, verbal fluency and praxis. The investigation began in 1999, by posing the evaluation of a cohort of patients with PD using neuropsychological tests and their correlation with the image of single photon emission computed tomography (SPECT), by the intravenous injection of a radioactive drug (99mTc HMPAO) to evaluate cerebral blood flow in different areas of the cerebral cortex and basal ganglia. The follow up was thought to be performed at 5 years of the first evaluation...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Psicología, Departamento de Psicobiología, leída el 20-01-2016